Patents by Inventor Thomas H. Bugge

Thomas H. Bugge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified anthrax toxin protective antigen
    Patent number: 10835593
    Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Assignee: The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Shi-Hui Liu, Stephen H. Leppla, Thomas H. Bugge, Alexander N. Wein, Diane E. Peters, Jie Liu, Kuang-Hua Chen
  • MODIFIED ANTHRAX TOXIN PROTECTIVE ANTIGEN
    Publication number: 20180250376
    Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Application
    Filed: August 25, 2016
    Publication date: September 6, 2018
    Applicant: The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Shi-Hui Liu, Stephen H. Leppla, Thomas H. Bugge, Alexander N. Wein, Diane E. Peters, Jie Liu, Kuang-Hua Chen
  • Multimeric protein toxins to target cells having multiple identifying characteristics
    Patent number: 8388933
    Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: March 5, 2013
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
  • MULTIMERIC PROTEIN TOXINS TO TARGET CELLS HAVING MULTIPLE IDENTIFYING CHARACTERISTICS
    Publication number: 20110280908
    Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.
    Type: Application
    Filed: April 15, 2011
    Publication date: November 17, 2011
    Applicants: Services, National Institutes of Health, Office of Technology Transfer
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
  • Multimeric protein toxins to target cells having multiple identifying characteristics
    Patent number: 7947289
    Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: May 24, 2011
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
  • HUMAN CANCER THERAPY USING ENGINEERED MATRIX METALLOPROTEINASE-ACTIVATED ANTHRAX LETHAL TOXIN THAT TARGETS TUMOR VASCULATUTURE
    Publication number: 20100168012
    Abstract: The present invention provides methods for inhibiting tumor associated angiogenesis by administering a mutant protective antigen protein comprising a matrix metalloproteinase-recognized cleavage site in place of the native protective antigen furin-recognized site in combination with a lethal factor polypeptide comprising a protective antigen binding site. Upon cleavage of the mutant protective antigen by a matrix metalloproteinase, the lethal factor polypeptide is translocated into cancer and endothelial cells and inhibits tumor associated angiogenesis.
    Type: Application
    Filed: December 14, 2007
    Publication date: July 1, 2010
    Applicant: The Government of the United States of America as Represented by the Secretary of the Department of
    Inventors: Stephen H. Leppla, Shihui Liu, Thomas H. Bugge, Brooke M. Curie